Relative Contributions of the Novel Diarylquinoline TBAJ-876 and its Active Metabolite to the Bactericidal Activity in a Murine Model of Tuberculosis
The Journal of Infectious Diseases · 2024
DOI: 10.1093/infdis/jiae332 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2024. Verfasst von Saskia E Mudde und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Center, Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: Tuberculosis, Mycobacterium tuberculosis, Antitubercular Agents, Diarylquinolines. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: TB Alliance.
Abstract (Originalsprache)
Background
TBAJ-876 is a next-generation diarylquinoline. In vivo, diarylquinoline metabolites are formed with activity against Mycobacterium tuberculosis. Species-specific differences in parent drug-to-metabolite ratios might impact the translational value of animal model-based predictions. This study investigates the contribution of TBAJ-876 and its major active metabolite, TBAJ-876-M3 (M3), to the total bactericidal activity in a mouse tuberculosis model.
Methods
In vitro activity of TBAJ-876 and M3 was investigated and compared to bedaquiline. Subsequently, a dose-response study was conducted in M. tuberculosis-infected BALB/c mice treated with TBAJ-876 (1.6/6.3/25 mg/kg) or M3 (3.1/12.5/50 mg/kg). Colony-forming units in the lungs and TBAJ-876 and M3 plasma concentrations were determined. M3's contribution to TBAJ-876's bactericidal activity was estimated based on M3 exposure following TBAJ-876 treatment and corresponding M3 activity observed in M3-treated animals.
Results
TBAJ-876 and M3 demonstrated profound bactericidal activity. Lungs of mice treated for 4 weeks with 50 mg/kg M3 were culture negative. Following TBAJ-876 treatment, M3 exposures were 2.2 to 3.6-fold higher than for TBAJ-876. TBAJ-876 activity was substantially attributable to M3, given its high exposure and potent activity.
Conclusions
These findings emphasize the need to consider metabolites and their potentially distinct exposure and activity profiles compared to parent drugs to enhance the translational value of mouse model-driven predictions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Center, Rotterdam, The Netherlands.
- Global Alliance for Tuberculosis Drug Development, New York, New York, USA.
- Department of Internal Medicine, Section of Infectious Diseases, Erasmus University Medical Center, Rotterdam, The Netherlands.
ORCID-Profile: Saskia E Mudde, Nicole C Ammerman
Förderung
- TB Alliance
Zitieren
APA
Mudde, S. E., Ammerman, N. C., Ten Kate, M. T., Fotouhi, N., Lotlikar, M. U., Bax, H. I., & de Steenwinkel, J. E. M. (2024). Relative Contributions of the Novel Diarylquinoline TBAJ-876 and its Active Metabolite to the Bactericidal Activity in a Murine Model of Tuberculosis. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiae332
Vancouver
Mudde SE, Ammerman NC, Ten Kate MT, Fotouhi N, Lotlikar MU, Bax HI, et al. Relative Contributions of the Novel Diarylquinoline TBAJ-876 and its Active Metabolite to the Bactericidal Activity in a Murine Model of Tuberculosis. The Journal of Infectious Diseases. 2024. doi:10.1093/infdis/jiae332
BibTeX
@article{Mudde2024,
author = {Mudde, Saskia E and Ammerman, Nicole C and Ten Kate, Marian T and Fotouhi, Nader and Lotlikar, Manisha U and Bax, Hannelore I and de Steenwinkel, Jurriaan E M},
title = {Relative Contributions of the Novel Diarylquinoline TBAJ-876 and its Active Metabolite to the Bactericidal Activity in a Murine Model of Tuberculosis},
journal = {The Journal of Infectious Diseases},
year = {2024},
doi = {10.1093/infdis/jiae332}
}
EUVIMED